Pelthos Therapeutics heads into its third-quarter report with an unusual disconnect. Last quarter, the company described a launch that was gathering speed: prescriptions, prescribers, refills and revenue all hit records, and adjusted EBITDA losses narrowed for a third straight quarter. Since then the stock has lost nearly two-thirds of its value. The November 12 release, due before the open, now has to show whether the Zelsuvmi story still holds through the summer and back-to-school months that management itself flagged as a risk for acute molluscum prescriptions.

The Street is asking for revenue of about $18.2 million, up roughly 146% from $7.4 million a year ago and about 17% above the $15.6 million reported last quarter. The consensus loss of $2.83 per share would be a sharp improvement from the $5.30 loss a year earlier. Per-share results have been noisy, though, because of fair-value accounting on related-party convertible notes, the issue that forced a restatement of the first-quarter filing. Revenue and adjusted EBITDA are the cleaner measures of progress. Management still does not give revenue or earnings guidance, so the consensus is effectively the analysts' extrapolation of last quarter's acceleration.

That extrapolation is not a given. Net product revenue went from $10.7 million to $15.4 million last quarter, helped by a 48% sequential jump in prescribed units to 11,925 and an 82% rise in refills. A further mid-teens increase would mean demand kept building through a period management warned could be soft. Weekly prescription data, the unique prescriber count, which reached 4,571 last quarter, and repeat writers will show whether new prescribers kept coming in and whether the August expert consensus guidelines, which called Zelsuvmi the only at-home molluscum option with meaningful clearance, are starting to change how dermatologists and pediatricians prescribe. Results that only hold flat would suggest the second quarter was partly a seasonal peak rather than a new baseline.

Margins and pricing could matter as much as volume. Cost of goods doubled to $3.6 million last quarter, partly because of a $0.9 million write-off of out-of-spec API that management said came from a procedural problem now fixed. A clean quarter without further inventory charges would back that up. Gross-to-net is a quieter variable. Management moved its framing to the low-to-mid 30% range from mid-to-high 30s unless a new payer contract is signed, and last quarter's figure was a favorable 29.6%. A creep higher would cut into the revenue gained from more scripts. Continued improvement on the adjusted EBITDA loss, which was $5.7 million last quarter, would keep the operating leverage story intact.

The balance sheet is the other pressure point. Cash fell to $24.2 million from $32 million in a single quarter, though trailing revenue passing $42 million gave the company access to another $10 million under its Horizon facility. Any update on cash burn, use of that tranche, or funding plans ahead of the Zepi launch, now set for March 2027, will likely weigh heavily on how the stock reacts.

Sentiment has turned sharply. Readings went from modestly bullish before the last report to deeply bearish now. At $10.15, the shares are well below the 200-day moving average near $24 and only slightly above the post-earnings low of $9.02, after trading between roughly $23.50 and $29.80 in the prior period. That decline lowers the bar for a positive reaction but also shows how little benefit of the doubt investors are giving. The central question is whether Zelsuvmi demand grew through the seasonal lull at stable pricing and with a manageable cash burn. If it did, last quarter's improving story holds. If prescriptions stalled or cash fell faster, the market's skepticism will look justified.